Assessment of Amikacin- and Capreomycin-Related Adverse Drug Reactions in Patients with Multidrug-Resistant Tuberculosis and Exploring the Role of Genetic Factors
No Thumbnail Available
Date
2023-04
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Following the introduction of all-oral treatment regimens for patients with drug-resistant tuberculosis (TB), second-line injectable drug applications have been reduced in the last few years. However, they are still important for anti-TB therapy. This study aims to analyze the occurrence of amikacin- and capreomycin-related adverse drug reactions (ADR) in patients with multidrug-resistant tuberculosis (MDR-TB) and evaluate the role of multiple patient-, disease-, and therapy-related factors on the frequency of the observed adverse events. In addition, the possible role of genetic risk factors was studied by full-length mitochondrial DNA sequencing. Toward this aim, we retrospectively evaluated 47 patients with MDR-TB who received amikacin and/or capreomycin. In total, 16 (34.0%) patients developed ototoxicity and 13 (27.7%) developed nephrotoxicity, including 3 (6.4%) patients who experienced both adverse events. Ototoxicity development was more common in patients who received amikacin. No other factors showed a significant impact. Nephrotoxicity was likely associated with previous renal health impairment. Full mitochondrial genome sequencing did not reveal any specific ADR-associated variants, and results showed no differences in adverse event occurrence for any specific variants, mutation count, or mitochondrial haplogroup. The absence of the previously reported ototoxicity-related mtDNA variants in our patients with ototoxicity and nephrotoxicity highlighted the complex nature of the ADR occurrence.
Description
Publisher Copyright: © 2023 by the authors.
Keywords
amikacin, capreomycin, MDR-TB, nephrotoxicity, ototoxicity, 3.1 Basic medicine, 3.2 Clinical medicine, 1.1. Scientific article indexed in Web of Science and/or Scopus database, Medicine (miscellaneous), SDG 3 - Good Health and Well-being
Citation
Freimane, L, Barkāne, L, Kivrane, A, Sadovska, D, Ulanova, V & Ranka, R 2023, 'Assessment of Amikacin- and Capreomycin-Related Adverse Drug Reactions in Patients with Multidrug-Resistant Tuberculosis and Exploring the Role of Genetic Factors', Journal of Personalized Medicine, vol. 13, no. 4, 599. https://doi.org/10.3390/jpm13040599